Etoposide/Trofosfamide: Off-label use, pulmonary embolism and neutropenia.

In a retrospective study, 22 patients with glioblastoma were described as developing neutropenia or pulmonary embolism during off-label treatment with trofosfamide and etoposide. The specific dosages, routes, durations of treatments, and outcomes were not provided. It was noted that the patients received off-label treatment with trofosfamide and etoposide, but experienced neutropenia (n=1) and pulmonary embolism (n=1) as a result. [Extracted from the article]